Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy

被引:0
作者
Li, Luzhen [1 ]
Chen, Ting [1 ]
Lai, Huiqin [1 ]
Zhang, Ao [1 ]
Zhao, Xianhui [1 ]
Wu, Jiaming [1 ]
Hong, Huisi [1 ]
Wu, Lexia [1 ]
Lin, Sihong [1 ]
Wang, Kexin [1 ]
Zhang, Huatang [1 ]
Fang, Cantu [1 ]
机构
[1] Guangzhou Univ Chinese Med, Zhongshan Affiliated Hosp, Zhongshan, Guangdong, Peoples R China
关键词
case report; immune checkpoint inhibitors; neoadjuvant therapy; nivolumab; non-small cell lung cancer; OPEN-LABEL; PEMBROLIZUMAB; KEYNOTE-024; MULTICENTER; EFFICACY;
D O I
10.1097/MD.0000000000029336
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: For locally advanced non-small cell lung cancer (NSCLC), the neoadjuvant therapy strategy of preoperative nivolumab combined with chemotherapy has great potential, especially for locally advanced NSCLC which are initially unresectable. They may be cured after neoadjuvant immunotherapy, and this may become a new direction of treatment. We hope that this representative medical record and literature review can provide some assistance for clinicians using immune checkpoint inhibitors to treat lung cancer. Patient concerns: A 50-year-old male patient was admitted to Zhongshan Hospital of Traditional Chinese Medicine on April 27, 2020 due to "coughing for more than one month.". The patient had nothing of note in either his medical history or that of his family, and no history of smoking. Diagnosis: The diagnosis was cT4N2M0IIIB stage right lower lung NSCLC with right hilar and mediastinal lymph node metastasis. The stage was inoperable stage IIIB NSCLC, but the patient had a strong willingness for doing surgery. Interventions: The patient received 3 rounds of the neoadjuvant nivolumab therapy combined with TP (paclitaxel plus cisplatin) regimen, on 5-14-21, 06-07-21 and 07-07-21. Outcomes: The tumor's area shrunk. Then the patient underwent thoracoscopic radical resection of the cancer in the right upper lung and postoperative pathology achieved pathological complete response (pCR) Lessons: In this case, combined with the wishes of the patient and the latest research results, we confirmed pCR by radical surgery after 3 rounds of the neoadjuvant nivolumab therapy combined with chemotherapy. This may be a modality to cure more lung cancer patients in the future.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Cellular changes in non-small cell lung cancer after neoadjuvant therapy
    Junker, K
    Müller, KM
    Abker, S
    Bosse, U
    Klinke, F
    Thomas, M
    [J]. PATHOLOGE, 2004, 25 (03): : 193 - 201
  • [32] A case of non-small cell lung cancer with long-term response after re-challenge with nivolumab
    Ito, Keima
    Oguri, Tetsuya
    Takeda, Norihisa
    Fukumitsu, Kensuke
    Fukuda, Satoshi
    Kanemitsu, Yoshihiro
    Tajiri, Tomoko
    Ohkubo, Hirotsugu
    Takemura, Masaya
    Maeno, Ken
    Ito, Yutaka
    Niimi, Akio
    [J]. RESPIRATORY MEDICINE CASE REPORTS, 2020, 29
  • [33] Neoadjuvant chemotherapy for non-small cell lung cancer
    Pinder-Schenck, M.
    Bepler, G.
    [J]. MINERVA CHIRURGICA, 2009, 64 (06) : 611 - 628
  • [34] Multiparametric MRI for evaluation of pathological response to the neoadjuvant chemo-immunotherapy in resectable non-small-cell lung cancer
    Bao, Xiao
    Bian, Dongliang
    Yang, Xing
    Wang, Zheming
    Shang, Mingdong
    Jiang, Gening
    Shi, Jingyun
    [J]. EUROPEAN RADIOLOGY, 2023, 33 (12) : 9182 - 9193
  • [35] Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition
    Luecke, E.
    Ganzert, C.
    Foellner, S.
    Waesche, A.
    Jechorek, D.
    Schoeder, V.
    Walles, T.
    Genseke, P.
    Schreiber, J.
    [J]. PNEUMOLOGIE, 2020, 74 (11): : 766 - 772
  • [36] Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review
    Yin, Cunli
    Hu, Bin
    Yang, Xi
    Kou, Lingna
    Tian, Bo
    Wang, Chenghao
    Li, Siru
    Liu, Bin
    Ge, Jun
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [37] Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
    Dai, Fuqiang
    Wu, Xiaoli
    Wang, Xintian
    Li, Kunkun
    Wang, Yingjian
    Shen, Cheng
    Zhou, Jinghai
    Niu, Huijun
    Deng, Bo
    Tan, Qunyou
    Wang, Ruwen
    Guo, Wei
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review
    van Eeden, Ronwyn
    Rapoport, Bernardo L.
    Smit, Teresa
    Anderson, Ronald
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [39] Pathological complete response to radical surgery after receiving durvalumab plus neoadjuvant chemotherapy for 1 limited-stage small cell lung cancer patient: a case report
    Li, Zhifeng
    Zhang, Boyi
    Yang, Fuyao
    Yang, Liwei
    [J]. TRANSLATIONAL CANCER RESEARCH, 2022, 11 (04) : 973 - 979
  • [40] Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery
    Dai, Peilin
    Rao, Xi
    Zhang, Xi
    Qiu, Enming
    Wu, Gang
    Lin, Yu
    Li, Sitong
    Li, Zhou
    Cai, Zhai
    Han, Shuai
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13